ClinicalTrials.gg
CompletedNCT00442221Updated Mar 1, 2007

The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months

A Phase 3 interventional study of Sumatriptan and Naproxen sodium in Migraine Headaches, sponsored by POZEN. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2007-03-01.

Sponsored by POZEN (part of Aralez Pharmaceuticals) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 42 studies testing sumatriptan in Migraine Disorders — none open to participants now, none under way, none of them phase 3. Sumatriptan · Migraine Disorders.

Enrollment
9th of 42
500 · median 74
Started
2004
the only one that year
Phase 3
18 of 42
none open now
Registered
7th of 42
by date

Among the 42 studies testing sumatriptan in Migraine Disorders, this one is the 9th largest by enrollment, is the only one that started in 2004, is one of 18 in phase 3, and was the 7th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 341 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

None of the 42 studies testing sumatriptan in Migraine Disorders is open now. The open studies under Migraine Disorders, anywhere →

Where they have run

About sumatriptan

Sumatriptan: first FDA approval 1992 (IMITREX STATDOSE (AUTOINJECTOR)). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 42 studies testing sumatriptan in Migraine Disorders as a file.
02

Study summary

The objective of this study is to assess the safety of a single-tablet dose of Combo Formulation for the treatment of moderate to severe migraines

Read the detailed description

The objective of this study is to assess the safety of a single-tablet dose of Combo Formulation for the treatment of moderate to severe migraines, with an optional second dose at least 2 hours following the first dose, if needed. Combo Formulation will be administered on average at least twice per month for 12 months.

03

Conditions studied

  • Migraine Headaches

Browse trials for

Keywords

  • Migrane headaches
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is a male or a female who is not pregnant or is not lactating. A female is eligible to enter and participate in this study if she is of:

    • Non- (i.e., physiologically incapable of becoming pregnant); or,
    • Child-bearing potential, has a negative pregnancy test (urine or serum) at screen, and employs one of the following acceptable measures of :

      • Complete abstinence from intercourse from 2 weeks prior to administration of the product, throughout the study, and for a time interval after completion or premature discontinuation from the study to account for elimination of the investigational drug (a minimum of 24 hrs); subjects utilizing this method must agree to use an alternate method of contraception if they should become sexually active and will be queried on whether they have been abstinent in the preceding 2 weeks when they present to the clinic for randomized treatment; or,
      • Female sterilization; or,
      • Sterilization of male partner; or,
      • Implants of levonorgestrel; or,
      • Injectable progestogen; or,
      • Oral contraceptive (combined or progestogen only); or,
      • Any intrauterine device (IUD) with published data showing that the lowest expected failure rate is less than 1% per year (not all IUDs meet this criterion); or,
      • Any other method with published data showing that the lowest expected failure rate for that method is less than 1% per year.
      • Barrier method only if used in combination with any of the above acceptable methods
  2. Subject is 18 - 65 years of age.
  3. Subject's first migraine occurred prior to the age of 50 years.
  4. Subject has at least a 6-month history, immediately prior to screening, of migraine with or without aura according to the International Headache Society criteria (see Appendix I).
  5. Subject experienced an average migraine headache frequency of 2-6 moderate or severe attacks per month in the previous 6 months.
  6. Subject is able to distinguish his/her migraine attacks as discrete from any other types of headaches.
  7. Subject is willing and able to give written prior to entry into the study.

Exclusion criteria

Exclusion Criteria:

  1. Subject has received another drug within the 4 weeks preceding this study, or subject was enrolled in this study previously.
  2. Subject has any concurrent medical or psychiatric condition that may affect the interpretation of efficacy and/or safety data or which otherwise contraindicates participation in a clinical trial with a new chemical entity. This includes, but is not limited to, chronic unstable debilitating diseases such as infection, multiple sclerosis, cancer, etc.
  3. Subject has a disorder that, in the opinion of the investigator, would result in the subject's inability to understand and comply with the requirements of the study.
  4. Subject has a history, symptoms, or signs of ischemic cardiac, cerebrovascular or peripheral vascular syndromes or other significant underlying cardiovascular diseases.
  5. Subject has a history of cardiac arrhythmias requiring medication or a history of a clinically significant (ECG) abnormality that, in the investigator's opinion, contraindicates participation in this study.
  6. Subject has a history of cerebrovascular abnormalities including stroke and/or .
  7. Subject who, in the investigator's opinion, is likely to have unrecognized cardiovascular disease, based on history or the presence of risk factors (e.g. hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of coronary artery disease, female with surgical or physiological menopause, or male over 40 years of age).
  8. Subject has evidence or history of ischemic abdominal syndromes, peripheral vascular disease or Raynaud syndrome.
  9. Subject has uncontrolled hypertension at screening (sitting systolic pressure >160 millimeters of mercury (mmHg), diastolic pressure >95 mmHg).
  10. Subject has a history of epilepsy or conditions associated with a lowered seizure threshold.
  11. Subject has a history of basilar or hemiplegic migraine.
  12. Subject has a history of impaired hepatic or renal function that, in the investigator's opinion, contraindicates participation in this study; or the subject has any other abnormal laboratory value of clinical significance for this study.
  13. Subject has a history of non-migraine (i.e., tension-type, sinus, etc.) headache frequency greater than or equal to 15 days/month in each of the 3 months prior to screening.
  14. Subject has had >6 migraine attacks/month in either of the 2 months prior to screening.
  15. Subject is currently taking a monoamine oxidase inhibitor (MAOI), has taken a MAOI within the 2 weeks prior to screening, or plans to take a MAOI within 2 weeks after treatment.
  16. Subject is currently taking any anti-coagulant (e.g., warfarin) or NSAID (except doses of aspirin ≤325 mg per day being used for cardiovascular prophylaxis) on a regular basis.
  17. Subject is currently taking, or has taken in the previous 3 months, a migraine prophylactic medication containing ergotamine, an ergot derivative (dihydroergotamine), or methysergide.
  18. Subject is currently taking, or has taken in the previous 4 weeks, herbal preparations containing St. John's Wort (Hypericum perforatum)
  19. Subject has , intolerance, or to the use of sumatriptan or naproxen sodium, any of its components, or any other 5-HT1 receptor agonist.
  20. Subject has a history of allergic reactions to naproxen preparations, including subject in whom aspirin or other NSAID drugs induce the syndrome of asthma, rhinitis, and nasal polyps.
  21. Subject is pregnant, actively trying to become pregnant, or breast-feeding.
  22. Subject is of and not using adequate measures.
  23. Subject has a recent history (in the past 3 months) suggestive of alcohol or drug abuse or dependence, including the overuse (abuse) of ergotamines and/or narcotics to treat migraines. Ergotamine abuse is daily use for 14 consecutive days or intermittent consumption exceeding 10 mg per week for any two weeks.
  24. Subject has participated in an investigational drug trial within the previous four weeks, or plans to participate in another study at any time during the period of this study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
500 participants

Interventions

06

What researchers measure

Primary outcomes

  1. END POINTS

  2. Adverse events, physical examination findings, vital signs and clinical laboratory findings will be evaluated.

07

Study locations

2 sites
  • POZEN Inc.
    Chapel Hill, North Carolina 27517, United States
  • Headache Wellness Center
    Greensboro, North Carolina 27401, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2004 and a completion of Aug 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2007
First posted
Mar 1, 2007
Start
May 2004
Completion
Aug 2004
Last update
Mar 1, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Mar 1, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00442221
Lead sponsor
POZEN
First posted
Mar 1, 2007
Start date
May 2004
Completion
Aug 2004
Last update
Mar 1, 2007

Study contacts

David Taylor
study director · POZEN

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sumatriptan · Naproxen

Start the discussion